Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SPY 130

Next Previous
Drug Profile

SPY 130

Alternative Names: PR-026; SPY-130; SPY001-SPY003; SPY001/SPY003

Latest Information Update: 24 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Paragon Therapeutics
  • Developer Paragon Therapeutics; Spyre Therapeutics
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ulcerative colitis

Most Recent Events

  • 13 Apr 2026 Efficacy and adverse events data from the phase II SKYLINE trial in Ulcerative colitis released by Spyre Therapeutics
  • 27 May 2025 Phase-II clinical trials in Ulcerative colitis in Ukraine, Taiwan, Spain, Switzerland, Slovakia, South Korea, Serbia, Romania, Poland, Japan, Italy, Israel, India, Hungary, Greece, Jordan, Moldova, Germany, Georgia, France, Czech Republic, Canada, Bulgaria, Bosnia-Herzegovina, Belgium, Austria, Australia, USA (IV) (NCT07012395)
  • 27 May 2025 Phase-II clinical trials in Ulcerative colitis in Ukraine, Taiwan, Spain, Switzerland, Slovakia, South Korea, Serbia, Romania, Poland, Japan, Italy, Israel, India, Hungary, Greece, Jordan, Moldova, Germany, Georgia, France, Czech Republic, Canada, Bulgaria, Bosnia-Herzegovina, Belgium, Austria, Australia, USA (SC) (NCT07012395)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top